Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Cyclerion Therapeutics (CYCN) Capital Expenditures (2019 - 2020)

Cyclerion Therapeutics (CYCN) has disclosed Capital Expenditures for 2 consecutive years, with $1.5 million as the latest value for Q4 2020.

For Q4 2020, Capital Expenditures rose 125.8% year-over-year to $1.5 million; the TTM value through Dec 2022 reached $44000.0, down 63.03%, while the annual FY2021 figure was $7000.0, 99.54% down from the prior year.
Capital Expenditures hit $1.5 million in Q4 2020 for Cyclerion Therapeutics, up from -$1.5 million in the prior quarter.
Across five years, Capital Expenditures topped out at $5.0 million in Q2 2019 and bottomed at -$5.9 million in Q4 2019.